Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Deborah J Marsh

Showing results (51-60 of 70) with videos related to

Pageof 7
Sort By:
Cellular Oncology (Dordrecht, Netherlands)|August 28, 2025
Revealing genetic drivers of ovarian cancer and chemoresistance: insights from whole-genome CRISPR-knockout library screensTali S Skipper, Kristie-Ann Dickson, Christopher E Denes, et al.
The Journal of Clinical Endocrinology and Metabolism|November 20, 2008
Accuracy of combined protein gene product 9.5 and parafibromin markers for immunohistochemical diagnosis of parathyroid carcinomaViive M Howell, Anthony Gill, Adele Clarkson, et al.
Human Molecular Genetics|June 27, 2023
CRISPR single base-editing: in silico predictions to variant clonal cell linesKristie-Ann Dickson, Natisha Field, Tiane Blackman, et al.
Oncogene|March 6, 2003
Novel succinate dehydrogenase subunit B (SDHB) mutations in familial phaeochromocytomas and paragangliomas, but an absence of somatic SDHB mutations in sporadic phaeochromocytomasDiana E Benn, Michael S Croxson, Kathy Tucker, et al.
Scientific Reports|May 19, 2016
Assessing mutant p53 in primary high-grade serous ovarian cancer using immunohistochemistry and massively parallel sequencingAlexander J Cole, Trisha Dwight, Anthony J Gill, et al.
Scientific Data|September 6, 2017
Comprehensive analyses of somatic TP53 mutation in tumors with variable mutant allele frequencyAlexander J Cole, Ying Zhu, Trisha Dwight, et al.
Molecular Therapy. Oncology|January 13, 2025
Drug repurposing screen targeting PARP identifies cytotoxic activity of efavirenz in high-grade serous ovarian cancerBayley Matthews, Michelle Wong-Brown, Dongli Liu, et al.
Endocrine-Related Cancer|December 23, 2009
CDC73/HRPT2 CpG island hypermethylation and mutation of 5'-untranslated sequence are uncommon mechanisms of silencing parafibromin in parathyroid tumorsMichael A Hahn, Viive M Howell, Anthony J Gill, et al.
The American Journal of Pathology|October 9, 2002
Independent genetic events associated with the development of multiple parathyroid tumors in patients with primary hyperparathyroidismTrisha Dwight, Anne E Nelson, George Theodosopoulos, et al.
Cancers|September 14, 2024
Aberrant SWI/SNF Complex Members Are Predominant in Rare Ovarian Malignancies-Therapeutic Vulnerabilities in Treatment-Resistant SubtypesYue Ma, Natisha R Field, Tao Xie, et al.
Pageof 7

Showing results (51-60 of 70) with videos related to

Sort By:
Pageof 7
Cellular Oncology (Dordrecht, Netherlands)|August 28, 2025
Revealing genetic drivers of ovarian cancer and chemoresistance: insights from whole-genome CRISPR-knockout library screensTali S Skipper, Kristie-Ann Dickson, Christopher E Denes, et al.
The Journal of Clinical Endocrinology and Metabolism|November 20, 2008
Accuracy of combined protein gene product 9.5 and parafibromin markers for immunohistochemical diagnosis of parathyroid carcinomaViive M Howell, Anthony Gill, Adele Clarkson, et al.
Human Molecular Genetics|June 27, 2023
CRISPR single base-editing: in silico predictions to variant clonal cell linesKristie-Ann Dickson, Natisha Field, Tiane Blackman, et al.
Oncogene|March 6, 2003
Novel succinate dehydrogenase subunit B (SDHB) mutations in familial phaeochromocytomas and paragangliomas, but an absence of somatic SDHB mutations in sporadic phaeochromocytomasDiana E Benn, Michael S Croxson, Kathy Tucker, et al.
Scientific Reports|May 19, 2016
Assessing mutant p53 in primary high-grade serous ovarian cancer using immunohistochemistry and massively parallel sequencingAlexander J Cole, Trisha Dwight, Anthony J Gill, et al.
Scientific Data|September 6, 2017
Comprehensive analyses of somatic TP53 mutation in tumors with variable mutant allele frequencyAlexander J Cole, Ying Zhu, Trisha Dwight, et al.
Molecular Therapy. Oncology|January 13, 2025
Drug repurposing screen targeting PARP identifies cytotoxic activity of efavirenz in high-grade serous ovarian cancerBayley Matthews, Michelle Wong-Brown, Dongli Liu, et al.
Endocrine-Related Cancer|December 23, 2009
CDC73/HRPT2 CpG island hypermethylation and mutation of 5'-untranslated sequence are uncommon mechanisms of silencing parafibromin in parathyroid tumorsMichael A Hahn, Viive M Howell, Anthony J Gill, et al.
The American Journal of Pathology|October 9, 2002
Independent genetic events associated with the development of multiple parathyroid tumors in patients with primary hyperparathyroidismTrisha Dwight, Anne E Nelson, George Theodosopoulos, et al.
Cancers|September 14, 2024
Aberrant SWI/SNF Complex Members Are Predominant in Rare Ovarian Malignancies-Therapeutic Vulnerabilities in Treatment-Resistant SubtypesYue Ma, Natisha R Field, Tao Xie, et al.
Pageof 7